CRP and endometrial cancer: Following adjustment for age, BMI, FIGO stage, disease grade, histology, LVSI, depth of myometrial invasion and baseline CRP, those with T2DM had a two-fold increase in the risk of death from endometrial cancer compared to those without (adjusted HR 2.15, 95% CI 1.05-4.39), p=0.035).